Biomarkers of interest to our group are linked to:

• Alzheimer’s disease and other neurodegenerative disorders
• General neurodegeneration
• Acute and chronic brain injury including both traumatic brain injury and stroke
• Inflammation
• The neurovascular system

Platforms used include SIMOA, Mass spect, Mesoscale discovery, FACS, and ELISAs, but also novel technology development (nanotech) for isolating biomarkers.

In alignment with MultiPark's strategic goals

• To develop accurate and cost-effective diagnostics using minimally invasive methods (for selecting appropriate therapies in time (personalized medicine).
• To promote clinical implementation of cutting edge findings.

Overarching goals

• Linking biomarker analysis to pathophysiology in neurodegeneration in order to understand disease mechanism and for detection, monitoring and prognosis of neurodegenerative disorders.
• Establish novel technologies for isolating biomarkers in relevant biofluids linked to neurodegenerative diseases.
• Accelerate scientific discoveries in the field of biomarkers by detection of synergies, increased collaborations and translation/implementation of new methods into the clinic.

Planned activities

Once a year, the group plans to organize workshops or symposia on techniques and/or the use of biomarkers.